​​​​​​​​​South East London Area Prescribing Committee

 

The South East London Area Prescribing Committee (APC) was established in 2013 and is a partnership committee which discusses and makes recommendations on medicines issues.

Partner NHS organisations in South East London who are part of the APC are:

Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark Clinical Commissioning Groups (CCGs),  Guys and St Thomas Foundation Trust, Kings College Hospital Foundation Trust,  South London and Maudsley Foundation Trust, Oxleas NHS Foundation Trust and Lewisham & Greenwich NHS Trust.

The committee also has representation from local Healthwatch organisations, NHS England London Area Team, and support from Medicines Information Services and the North East London Commissioning Support Unit.


Its aims are;

  • To provide a collective clinical leadership committee to ensure co-operation and consistency of approach to medicines optimisation across South East London
  • To enable all clinicians and commissioners to work together to ensure that patients have safe and consistent access to  medicines with the best outcomes
  • To advise on implementation of best practice around medicines, including National Institute for Health and Care Excellence ( NICE) guidelines and technology appraisals to encourage rapid and consistent implementation
  • To enable local NHS stakeholders and clinicians to exert a population approach to the prioritisation, improvement and quality of healthcare related to medicines.

The Medicines and Pathways Review Group is a working group of the APC which meets monthly to assess new medicines for prescribing within South East London, where these are intended to be prescribed in primary care or commissioned by Clinical Commissioning Groups.  Where primary care or commissioned medicines are subject to a new NICE technology appraisal, the APC will advise on best adoption and implementation in line with NICE. South East London wide treatment pathways and prescribing guidelines are also developed through the Committee and its sub-groups. 

The Local Trusts retain a Joint Formulary Committee which considers new drugs and changes of use of existing drugs which are used only within hospitals and are not subject to any specific commissioning arrangements.

If you are a South East London clinician and you wish to make an application for a new medicine to be considered by the APC please contact your local trust formulary pharmacist or, for primary care applications, your CCG medicines team.

Correspondence to the APC should be directed to:

T: 020 3049 4197

E: lamccg.medicinesoptimisation@nhs.net


  
  
APC Position Statement PS-001 Biosimilar Infliximab Sept 2015.pdf
  
APC Position Statement PS-002 Sativex MS spasticity  Dec 2015.pdf
  
APC Position Statement PS-003 Biosimilar Glargine Position June 2017.pdf
  
APC Position statement PS-004 Freestyle Libre FINAL July 2018.pdf
  
APC Position Statement PS-005 Ulipristal aceteate interim statement Mar 18.pdf
  
APC Position Statement PS-006 Rubefacients August 2018.pdf
  
APC Position statement PS-007 Lutein Antioxidants August 2018.pdf
  
APC Position statement PS-008 Tramadol-paracetamol August 2018.pdf
  
APC Position statement PS-009 Dosulepin August 2018.pdf
  
APC Position statement PS-010 Trimipramine August 2018.pdf
  
APC Position statement PS-011 Lidocaine August 2018.pdf
  
Recommendation 001 Lixisenatide in T2Diabetes.pdf
  
Recommendation 002 insulin degludec adults (withdrawn) July 2017.pdf
  
Recommendation 003 dapagliflozin type 2 diabetes (withdrawn) Nov 16.pdf
  
Recommendation 004 mirabegron for OAB (withdrawn) April 2016.pdf
  
Recommendation 005 Lisdexamfetamine ADHD children Sep 18.pdf
  
Recommendation 006 Combodart.pdf
  
Recommendation 007 Linaclotide in IBS  Nov 2017.pdf
  
Recommendation 008 Dymista for allergic rhinitis (withdrawn) June 2017.pdf
  
Recommendation 009 Lixisenatide in combination with insulin.pdf
  
Recommendation 010 Ingenol Mebutate for AK in adults updated Dec 15.pdf
  
Recommendation 011 Relvar Ellipta Astham - COPD (withdrawn) July 2016 V1.pdf
  
Recommendation 012 Diltiazem cream for anal fissures.pdf
  
Recommendation 013 Plenadren® tablets Adrenal insufficiency Sept 14.pdf
  
Recommendation 014 Levonorgestrel (Jaydess®) Intrauterine device Sept 14.pdf
  
Recommendation 015 Aripiprazole depot injection for schizophrenia FINAL.pdf
  
Recommendation 016 Golimumab in UC (withdrawn) April 2015.pdf
  
Recommendation 017 Vedolizumab in Crohns disease (withdrawn) Oct 2015.pdf
  
Recommendation 018 tadalafil post prostatectomy (withdrawn) May 2017.pdf
  
Recommendation 019 Vesomni  for LUTs (GREY) Oct 2017 FINAL.pdf
  
Recommendation 020 Trospium overactive bladder in children FINAL.pdf
  
Recommendation 021 Ulipristal pre-op fibroids (withdrawn) Feb 2018.pdf
  
Recommendation 022 Anakinra for acute gout FINAL.pdf
  
Recommendation 023 Vedolizumab in UC (withdrawn) FINAL June 2015.pdf
  
Recommendation 024 Paliperidone depot schizophrenia adults (AMBER)  Nov 15.pdf
  
Recommendation 025 Lurasidone for schizophrenia in adults (RED) Nov 15.pdf
  
Recommendation 026 Dapoxetine for premature ejaculation Mar 2015.pdf
  
Recommendation 027 Ketotifen for food allergy Nov 17.pdf
  
Recommendation 028 Nalcrom food allergy update June 2017.pdf
  
Recommendation 029 SURGIFLO® for Intraoperative bleeding (Neurosurgery) Mar 2015.pdf
  
Recommendation 030 Altoderm™ for mastocytosis in children April 2015.pdf
  
Recommendation 031Ropinirole MR Parkinson's Disease April 2015.pdf
  
Recommendation 032 Midodrine for IST and POTS (AMBER 3) Jan 18.pdf
  
Recommendation 033 ivabradine for IST and POTS (AMBER 3) Jan 18.pdf
  
Recommendation 034 Olopatadine in seasonal allergic conjunctivitis June 2015.pdf
  
Recommendation 035 timolol eye gel for raised intraocular pressure June 2015.pdf
  
Recommendation 036 Simbrinza for raised intraocular pressure June 2015.pdf
  
Recommendation 037 octreotide for chylothorax August 2015.pdf
  
Recommendation 038 ketamine oral solution in palliative care (RED) Oct 2015.pdf
  
Recommendation 039 depot medroxyprogesterone (Sayana Press) subcut  Nov 2015.pdf
  
Recommendation 040 Dexamfetamine Adult ADHD (AMBER) Dec 2015.pdf
  
Recommendation 041 Lisdexamfetamine Adult ADHD (AMBER) Dec 2015.pdf
  
Recommendation 042 Alteplase for massive  sub massive PE (RED) Dec 2015.pdf
  
Recommendation 043 daily tadalafil for ED non-responsive to PRN (GREY) Dec 2015.pdf
  
Recommendation 044 Duloxetine for Stress Urinary Incontinence  Dec 2015.pdf
  
Recommendation 045 Budesonide (Cortiment) for Ulcerative Colitis Dec 2015.pdf
  
Recommendation 046 Methylphenidate  Dexamfetamine Hypersomnia Feb 2016.pdf
  
Recommendation 047 Dexamfetamine for Narcolepsy (RED) Feb 2016.pdf
  
Recommendation 048 Tiotropium Respimat in Asthma (AMBER) March 2016.pdf
  
Recommendation 049 botulinum toxin hypersalivation  (RED) June 2016.pdf
  
Recommendation 050 Brivaracetam epilepsy (AMBER) FINAL.pdf
  
Recommendation 051 Botulinum toxin in Temporomandibular jaw September 2016.pdf
  
Recommendation 052 Guanfacine ADHD children (AMBER 3) Sep 2018.pdf
  
Recommendation 053 Dulaglutide in Type 2 diabetes mellitus September 2016.pdf
  
Recommendation 054 HPV vaccine for genital warts April 2017.pdf
  
Recommendation 055 Enstilar for psoriasis Nov 16.pdf
  
Recommendation 057 botulinum toxin in diabetic gastroparesis  Dec 16.pdf
  
Recommendation 058 Insulin glargine  (Toujeo) for Type 2 Diabetes  Dec 16.pdf
  
Recommendation 059 Insulin degludec (AMBER)  July 2017.pdf
  
Recommendation 060 gabapentin  pregabalin  in RLS.pdf
  
Recommendation 061 clonazepam in RLS.pdf
  
Recommendation 062 Opioids in RLS.pdf
  
Recommendation 063 Pitolisant for narcolepsy.pdf
  
Recommendation 064 Clonidine patches for dystonia April 2017.pdf
  
Recommendation 065 rivaroxaban pelvic fracture May 2017.pdf
  
Recommendation 066 anti MAP therapy for IBD May 2017.pdf
  
Recommendation 067 Dymista for allergic rhinitis June 2017.pdf
  
Recommendation 068 Brimonidine gel (Mirvaso) June 2017 (.pdf
  
Recommendation 069 Moxifloxacin eye drops June 2017.pdf
  
Recommendation 070 botulinum oesophageal spasm(RED)  July 2017.pdf
  
Recommendation 071 botulinum toxin achalasia (RED)  July 2017.pdf
  
Recommendation 072 collagenase Peyronies (GREY) July 2017.pdf
  
Recommendation 073 Duavive HRT (AMBER2) August 2017.pdf
  
Recommendation 074 Tioguanine IBD (RED) Sept 2017.pdf
  
Recommendation 075 Golimumab 100mg IBD Sept 2017.pdf
  
Recommendation 076 Ferric maltol IBD (AMBER2) Sept 2017.pdf
  
Recommendation 077 hyperhidrosis (GREEN) October 2017.pdf
  
Recommendation 078 ciclosporin eyedrops VKC  AKC childen (AMBER2) Nov 17.pdf
  
Recommendation 079 Velphoro (RED) Dec 2017.pdf
  
Recommendation 080 Oestrogen gels in menopause April 2018.pdf
  
Recommendation 081 botulinum anal fissure (RED) May 2018.pdf
  
Recommendation 082 Efracea (green) FINAL May 2018.pdf
  
Recommendation 083 Ivermectin (green)  FINAL May 2018.pdf
  
Recommendation 084 Trelegy and Trimbow COPD AMB 1 June 2018.pdf
  
Recommendation 085 Spiriva Respimat COPD GREEN June 2018.pdf
  
Recommendation 086 Spiolto COPD GREEN June 2018.pdf
  
Recommendation 087 opicapone in Parkinson's Disease July 2018.pdf
  
Recommendation 088 Narcolepsy cataplexy Aug 18.pdf
  
Recommendation 089 Non-REM parasomnia Aug 18.pdf
  
Recommendation 090 REM Behaviour Disorder (AMBER) Aug 18.pdf
  
Recommendation 091 REM Behaviour Disorder (RED) Aug 18.pdf
  
Recommendation 092 Levosert and Kyleena August 2018.pdf
  
Recommendation 093 desmopressin (Noqdirna) FINAL Sep 2018 (RED).pdf